New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:49 EDTHPTXHyperion Therapeutics completes acquisition of Andromeda Biotech
Hyperion Therapeutics announced that it has completed its previously announced acquisition of Andromeda Biotech. The acquisition broadens Hyperion's pipeline to include DiaPep277, a potentially first-in-class immunotherapy for new onset Type 1 diabetes that is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds Orphan Drug designation in the U.S.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
10:19 EDTHPTXHyperion Therapeutics management to meet with Needham
Subscribe for More Information
February 27, 2015
07:20 EDTHPTXHyperion Therapeutics could be a takeout target, says Brean Capital
Subscribe for More Information
February 26, 2015
16:38 EDTHPTXHyperion Therapeutics sees 2015 revenue $120M-$128M, consensus $119.3M
Subscribe for More Information
16:38 EDTHPTXHyperion Therapeutics reports Q4 adjusted EPS 47c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use